Rocuronium Pediatric Dose — Neuromuscular Blockade
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic receptor of the neuromuscular junction. It is widely used in pediatric rapid sequence intubation (RSI) and procedural paralysis due to its rapid onset compared with other nondepolarizing agents. Rocuronium is a preferred alternative to succinylcholine when depolarizing agents are contraindicated.
Pediatric Dosing
- Standard intubating dose: 0.5–1 mg/kg IV per dose
- Duration of action: approximately 15–45 minutes
Doses at the higher end of the range (1 mg/kg IV) are typically used for RSI to optimize intubating conditions and achieve the fastest possible onset. Lower doses (0.5 mg/kg) may be appropriate for less time-critical paralysis or shorter procedures.
Worked example: For a 20 kg child: 20 × 1 mg/kg = 20 mg IV (high-end RSI dose); or 20 × 0.5 mg/kg = 10 mg IV (low-end dose). Consult institutional protocol for maximum single-dose guidance.
Indications and Clinical Context
Rocuronium is indicated for facilitation of endotracheal intubation, particularly in pediatric RSI, and for short-term neuromuscular relaxation during procedures. As the fastest-onset nondepolarizing neuromuscular blocker available, it is frequently selected when succinylcholine is contraindicated — for example, in patients at risk for hyperkalemia, malignant hyperthermia, or with known myopathies. PALS and emergency airway guidelines recognize rocuronium as an appropriate RSI paralytic in the pediatric population.
Its duration of action (15–45 minutes) is longer than succinylcholine, which has important implications for the “cannot intubate, cannot oxygenate” scenario; providers should ensure airway rescue equipment and reversal agents (sugammadex) are immediately available before administration.
Administration and Monitoring
Rocuronium is administered as an IV bolus. Intraosseous (IO) access may be used if IV access is unavailable, consistent with resuscitation protocols. It should always be preceded by appropriate sedation/induction analgesia, as rocuronium provides no sedation or analgesia. Onset is typically within 60–90 seconds at the 1 mg/kg dose.
- Administer only after adequate sedation/induction agent has been given
- Have bag-mask ventilation and intubation equipment immediately available prior to dosing
- Monitor for adverse effects: tachycardia, hypotension (less common than with succinylcholine), and rare anaphylaxis
- Sugammadex is the reversal agent for rocuronium-induced neuromuscular blockade; consult institutional protocol for reversal dosing
- Use with caution in patients with hepatic impairment, as rocuronium is primarily hepatically eliminated
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.